HOME >> BIOLOGY >> NEWS
Study on chromosome ends may aid cancer research

PRINCETON, N.J. -- A Princeton scientist has discovered a mechanism that cells use to control the length of their chromosome ends, a process that is thought to go awry in cancer.

The finding, reported in the August 4 issue of Science by Professor of Molecular Biology Virginia Zakian and colleagues, may provide cancer researchers with clues for designing treatments.

Zakian found a naturally occurring protein that inhibits the activity of another protein, called telomerase, which replicates and lengthens the very ends of chromosomes. The protein, called Pif1p, acts directly on the chromosome ends, called telomeres, to keep the lengthening process in check, Zakian's research group reported.

Researchers have been studying telomerase with great intensity for the past 15 years because it appears to play a central role in the way cells age or become cancerous. Studies have shown that telomerase is present in 90 percent of cancer types, but is absent from most healthy cells. Cancer researchers have thus looked for ways to interfere with telomerase. Zakian's research suggests that mimicking or enhancing the action of Pif1p may be a good way to do so.

Telomerase builds structures called telomeres at the ends of chromosomes, like plastic caps at the ends of shoelaces. In normal conditions, telomeres shorten each time a cell divides, eventually exposing the genetic material and causing the cell to die. In cancer cells, however, telomerase keeps rebuilding the telomere caps, preventing the cell from undergoing its normal aging process.

In 1994, Zakian and collaborator Vincent Schulz reported that Pif1p keeps telomeres from lengthening. It remained unclear, however, how Pif1p accomplished that feat. There are many natural substances that could inhibit telomere lengthening in indirect ways, Zakian said. The new paper shows that Pif1p acts on the telomerase pathway itself and interacts directly with telomeric DNA, a potentially attractive feature for drug de
'"/>

Contact: Steven Schultz
sschultz@princeton.edu
609-258-5729
Princeton University
3-Aug-2000


Page: 1 2

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study chromosome ends may aid cancer research

(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:8/28/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... the development of autologous cell therapies, today reported ... 2015, corporate highlights, and near-term milestones.  The company,s ... www.sedar.com ,  www.edgar.com and at ... to launch its RCS-01 treatment for aging and ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas ... investment firms and animal health companies to hear from animal health companies with ... have also received licensing agreements or distribution contracts. This meeting is one ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
Cached News: